Blue light cystoscopy for the diagnosis of bladder cancer: Results from the US prospective multicenter registry

Siamak Daneshmand(Unknown), Badrinath R. Konety(Allina Health), Kamal S. Pohar(The Ohio State University), Trinity J. Bivalacqua(University of Pennsylvania), Joseph C. Liao(VA Palo Alto Health Care System), Jennifer M. Taylor(Michael E. DeBakey VA Medical Center), Jeffrey M. Holzbeierlein(University of Kansas Medical Center), Soroush Bazargani(University of Southern California), James P. Tierney(Charleston Area Medical Center), Brian Willard(Carolina Urology Partners)
Urologic Oncology Seminars and Original Investigations
May 30, 2018
10.1016/j.urolonc.2018.04.013
Cited by 112

Related Papers

Neurohumoral Features of Myocardial Stunning Due to Sudden Emotional Stress
|New England Journal of Medicine|2005|3.1k
ctDNA guiding adjuvant immunotherapy in urothelial carcinoma
|Nature|2021|603
Pembrolizumab monotherapy for the treatment of high-risk non-muscle-invasive bladder cancer unresponsive to BCG (KEYNOTE-057): an open-label, single-arm, multicentre, phase 2 study
|The Lancet Oncology|2021|532
Intravesical nadofaragene firadenovec gene therapy for BCG-unresponsive non-muscle-invasive bladder cancer: a single-arm, open-label, repeat-dose clinical trial
|The Lancet Oncology|2020|459
Adjuvant atezolizumab versus observation in muscle-invasive urothelial carcinoma (IMvigor010): a multicentre, open-label, randomised, phase 3 trial
|The Lancet Oncology|2021|411